Clinical TrialsEarly efficacy data for FT819 in 5 patients are very encouraging, especially given its off-the-shelf nature and reduced conditioning differentiation.
Operational StrategyThe company guides to meeting with the FDA to discuss potential registrational pathways, highlighting the potential to move straight into registrational studies.
Safety ProfileFT819 has demonstrated a clean safety profile thus far, aside from a single case of grade 2 CRS in a patient.